- Home
- NAUT vs NKTR Comparison
NAUT vs NKTR Comparison
Compare NAUT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- NKTR
- Stock Information
- Founded
- NAUT 2016
- NKTR 1990
- Country
- NAUT United States
- NKTR United States
- Employees
- NAUT N/A
- NKTR N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- NKTR Health Care
- Exchange
- NAUT Nasdaq
- NKTR Nasdaq
- Market Cap
- NAUT 284.7M
- NKTR 247.9M
- IPO Year
- NAUT N/A
- NKTR 1994
- Fundamental
- Price
- NAUT $1.76
- NKTR $0.93
- Analyst Decision
- NAUT Hold
- NKTR Buy
- Analyst Count
- NAUT 3
- NKTR 3
- Target Price
- NAUT $3.58
- NKTR $4.00
- AVG Volume (30 Days)
- NAUT 172.2K
- NKTR 2.3M
- Earning Date
- NAUT 10-29-2024
- NKTR 11-07-2024
- Dividend Yield
- NAUT N/A
- NKTR N/A
- EPS Growth
- NAUT N/A
- NKTR N/A
- EPS
- NAUT N/A
- NKTR N/A
- Revenue
- NAUT N/A
- NKTR $93,137,000.00
- Revenue This Year
- NAUT N/A
- NKTR $12.85
- Revenue Next Year
- NAUT N/A
- NKTR N/A
- P/E Ratio
- NAUT N/A
- NKTR N/A
- Revenue Growth
- NAUT N/A
- NKTR 5.53
- 52 Week Low
- NAUT $1.74
- NKTR $0.47
- 52 Week High
- NAUT $3.46
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- NAUT 30.63
- NKTR 33.04
- Support Level
- NAUT $1.88
- NKTR $0.89
- Resistance Level
- NAUT $2.10
- NKTR $1.04
- Average True Range (ATR)
- NAUT 0.16
- NKTR 0.07
- MACD
- NAUT -0.02
- NKTR -0.00
- Stochastic Oscillator
- NAUT 3.77
- NKTR 14.81
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.